HC Wainwright reiterated their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2024 earnings at ($1.33) EPS and FY2025 earnings at ($3.31) EPS.
A number of other equities analysts have also weighed in on MBRX. StockNews.com initiated coverage on shares of Moleculin Biotech in a report on Tuesday, February 25th. They issued a “sell” rating on the stock. Maxim Group lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.
Check Out Our Latest Research Report on MBRX
Moleculin Biotech Trading Up 7.4 %
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Read More
- Five stocks we like better than Moleculin Biotech
- 3 Best Fintech Stocks for a Portfolio Boost
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Quiet Period Expirations Explained
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- The How And Why of Investing in Oil Stocks
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
